NICE’s decisions for both drugs are not final and are pending more evidence. Credit: Art_Photo via Shutterstock. On 23 ...

ImmunityBio has announced the commencement of a Phase I trial evaluating its CD19 (t-haNK) cell therapy for the treatment of ...

Germany-based Ottobock SE & Co. KGaA will hold an approximate 10% stake in Onward’s share capital following the investment.

OKYO Pharma has initiated the Phase II trial of OK-101, a treatment for neuropathic corneal pain (NCP), by dosing the first ...